Efmarodocokin alfa: meta-analysis of COVID-19 studies

All studies   Mortality   Recovery   RCTs   RCT mortality   Peer-reviewed   All outcomes  
0 0.5 1 1.5+ All studies -15% 1 266 Improvement, Studies, Patients Relative Risk Mortality -15% 1 266 RCTs -15% 1 266 Late -15% 1 266 Efmarodocokin Alfa for COVID-19 c19early.org December 2025 Favorsefmarodocokin alfa Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] death 17/132 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Late treatment -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk All studies -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk 1 efmarodocokin alfa COVID-19 study c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Effect extraction pre-specified(most serious outcome) Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] 17/132 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Late treatment -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk All studies -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk 1 efmarodocokin alfa COVID-19 mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) 13% 0.87 [0.65-1.16] no recov. 132 (n) 134 (n) Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.35 Late treatment 13% 0.87 [0.65-1.16] 132 (n) 134 (n) 13% lower risk All studies 13% 0.87 [0.65-1.16] 132 (n) 134 (n) 13% lower risk 1 efmarodocokin alfa COVID-19 recovery result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.35 Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] death 17/132 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Late treatment -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk All studies -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk 1 efmarodocokin alfa COVID-19 Randomized Controlled Trial c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Effect extraction pre-specified(most serious outcome) Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] 17/132 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Late treatment -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk All studies -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk 1 efmarodocokin alfa COVID-19 RCT mortality result c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] death 17/132 15/134 Improvement, RR [CI] Treatment Control Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Late treatment -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk All studies -15% 1.15 [0.59-2.11] 17/132 15/134 15% higher risk 1 efmarodocokin alfa COVID-19 peer reviewed studies c19early.org December 2025 Tau​2​ = 0.00, I​2​ = 0.0%, p = 0.69 Effect extraction pre-specified(most serious outcome) Favors efmarodocokin alfa Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ COVASTIL Waters (DB RCT) -15% 1.15 [0.59-2.11] death 17/132 15/134 Improvement, RR [CI] Treatment Control COVASTIL Waters (DB RCT) 13% 0.87 [0.65-1.16] no recov. 132 (n) 134 (n) Efmarodocokin alfa COVID-19 outcomes c19early.org December 2025 Favors efmarodocokin alfa Favors control